Observational Study Evaluating Safety and Effectiveness of Cabozantinib in Adults with Neuroendocrine Tumors After Prior Systemic Treatment

What this Trial Is About

Researchers are studying how well cabozantinib works and how safe it is for adults with neuroendocrine tumors NETs, a type of cancer that can develop in various parts of the body. All participants have previously received at least one systemic treatment for their cancer, but their disease has continued to progress. This observational study takes place in regular hospitals and clinics in Germany and Austria, involving about 150 participants. Participants receive cabozantinib as part of their usual medical care, without any extra tests or procedures beyond routine clinical practice. Doctors collect data from regular medical visits, scans, and tests to monitor how the cancer responds to treatment and how long participants stay on cabozantinib. The study also observes side effects and assesses quality of life using questionnaires over time. Throughout the study, participants undergo evaluations including scans and laboratory tests at baseline and every three months for up to 18 months. Researchers track outcomes such as disease control rate at 6 months, progression-free survival, treatment duration, side effects, and quality of life changes. The study follows participants until the end of 2028 to gather comprehensive information on the treatment course and patient experiences.

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment